Posted by Michael Wonder on 26 Jul 2022
TGA gives a tick to Scemblix
26 July 2022 - Asciminib is an oral and potent inhibitor of Abelson non-receptor tyrosine kinases/breakpoint cluster region (ABL/BCR): ABL1 tyrosine kinases.
Scemblix is indicated for the treatment of patients 18 years of age and above with:
- Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase previously treated with two or more tyrosine kinase inhibitors
- Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase with the T315I mutation.
